Lyell Immunopharma Inc. (NASDAQ: LYEL) will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE